All data are based on the daily closing price as of August 28, 2025
h
Hugel
145020.KQ
228.71 USD
-0.69
-0.30%
Overview
Last close
228.71 usd
Market cap
2.46B usd
52 week high
286.69 usd
52 week low
131.68 usd
Target price
333.77 usd
Valuation
P/E
N/A
Forward P/E
22.3214
Price/Sales
8.8072
Price/Book Value
4.0138
Enterprise Value
2.16B usd
EV/Revenue
7.4353
EV/EBITDA
15.0525
Key financials
Revenue TTM
280.35M usd
Gross Profit TTM
215.80M usd
EBITDA TTM
141.37M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
743.98M usd
Net debt
N/A usd
About
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.